Europe Biopharmaceutical Logistics Market Size & Outlook, 2025-2033
Europe Biopharmaceutical Logistics Market Insights
- As highlighted in Reed Intelligence analysis, the Europe Biopharmaceutical Logistics Market, valued at USD 37658.97 Million in 2024, is estimated to achieve USD 73886.87 Million by 2033.
- The market is estimated to grow at a CAGR of 7.76% spanning 2025 to 2033.
- By market size, Cold Chain led the By Supply Chain category in 2024.
- The By Supply Chain segment led by Cold Chain is estimated to post the fastest growth, sustaining its position as the most lucrative during the forecast timeframe.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- Europe represented 26.3% of the global Biopharmaceutical Logistics Market size in 2024.
- By 2033, United States is estimated to hold the largest position in the global market in terms of size.
- Russia is estimated to remain the fastest-growing market in Europe, advancing to USD 6605.79 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 37658.97 Million |
| Market Size In 2033 | USD 73886.87 Million |
| Largest segment | Cold Chain |
| Units | Revenue in USD Million |
| CAGR | 7.76% (2025-2033) |
| Segmnetation Covered | |
| Europe |
|
| By Supply Chain |
|
| By Services |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Europe Biopharmaceutical Logistics Market Country 2025-2033 (USD Million)
| Europe | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Germany | XX.x | XX.x | XX.x | 9603.04 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| United Kingdom | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| France | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Italy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Spain | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Russia | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Nordic | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Benelux | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Europe Biopharmaceutical Logistics Market By Supply Chain 2025-2033 (USD Million)
| By Supply Chain | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cold Chain | XX.x | XX.x | XX.x | 21209.53 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Non-Cold Chain | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Europe Biopharmaceutical Logistics Market By Services 2025-2033 (USD Million)
| By Services | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mode of Transportation | XX.x | XX.x | XX.x | 18441.6 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Warehousing | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
